Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
about
Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40)Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease.Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging.Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profileThe Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty.Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluid.CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease.A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood.The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials.Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease.Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid.Applying fluid biomarkers to Alzheimer's disease.The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes.New CSF biomarkers on the block.Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke.Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease.Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development.Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease.Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers.APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease.A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.LPS-induced cortical kynurenic acid and neurogranin-NFAT signaling is associated with deficits in stimulus processing during Pavlovian conditioning.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.Citalopram Ameliorates Synaptic Plasticity Deficits in Different Cognition-Associated Brain Regions Induced by Social Isolation in Middle-Aged Rats.An N-terminal motif unique to primate tau enables differential protein-protein interactions.Neurogranin as a predictor of memory and executive function decline in MCI patients.CSF neurogranin or tau distinguish typical and atypical Alzheimer disease.Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer's disease in late-middle-aged adults.Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease.Intrahippocampal injection of a lentiviral vector expressing neurogranin enhances cognitive function in 5XFAD mice.
P2860
Q33771776-647C205E-664F-42C0-B0F8-AA032590848BQ36402008-E6117EDF-FB7E-4DB5-97F7-062BD42F4508Q36439886-60E830F1-2D36-4AE6-95C6-EA73E0834098Q36885492-C125CCC0-887F-4A66-A30C-4DED4971E43DQ36891744-595351CC-3B0D-47BB-A48E-D9C5117EFBA4Q37049024-70BA3502-261E-4F7E-ABA3-70BF49DF4D81Q37169136-64F54B32-3848-4723-A2E1-521DC40A8798Q37297626-9CEDEA6E-46D4-4419-9ABF-055871806636Q37307467-75B04647-F78F-4AC0-9B4B-054AF9367A9BQ37432083-4BDCF649-6A8D-45F8-BAFC-36B26A8299E2Q37505536-53BC1FED-E0F0-456A-8443-394DACF4716DQ38653401-E3D6959D-A1C4-442B-A184-FEABB6053807Q38672062-1AC556C4-CAFA-4CA5-B691-A94F1C40BB8FQ38873321-E17F8D5E-9483-483E-98D7-7EBA1892D8CCQ39217840-BB0CCAC1-AA49-4A70-AD1B-A86284048262Q39251035-C4D644B4-5211-4D53-BCB9-FC72B36DF5EDQ39432793-3DDD9002-F67C-4C9A-BD0A-64305F3E6102Q41203311-A19128B4-296C-46EA-AE49-0B6572D89F75Q41293029-F0AB2F6C-0913-4F45-8A69-8B0618481BD8Q41571333-00C68FB1-A5AF-4778-88EF-6344401CAA1BQ42655670-A7E81570-2D69-4B7B-9D02-AFD92AC56C86Q42656279-950A0AA0-F60D-42FD-869C-020FA31CABAAQ44909742-9E59378E-95BA-4B35-8FA6-588968409021Q46490492-C275F2BF-692B-455D-AB59-99A4EE24A0ECQ47100604-739B088B-124B-4A0F-AD58-A7CF3AFAAF0DQ47107905-F59449D4-FAED-40A8-9A34-9BD8B4CD3922Q47200597-72DCD30A-46FD-496F-AE6A-6AEF17C12811Q47387394-E35BFE14-5E63-4A63-B5BE-0893DD8E9C6AQ47587631-16E7136A-4E7B-4BB7-874D-0B68B1D94F3CQ47958922-17585837-BD34-455C-BD7A-528B07355675Q48185391-10BA4D1F-AFC5-4CAC-930C-8FBA5FE5B74DQ48889714-63CD7CF6-FA3A-4233-AF7B-9C8A0E7F2C22Q49571817-7264D6D4-D2B2-4A1F-B8DF-E70FF29FADAFQ50048402-AA8CF7E2-D129-4A05-88F7-2EB9BCFEF7EDQ50233550-F5F02569-FE99-4CB0-8EC8-2A2D79061545Q50591921-13669559-7D22-4BE8-9024-2FD088055AECQ51359685-08645325-881B-478C-B322-A960958FF9E9Q52589491-FEB48572-2BFD-46F1-A1F1-84DE77BF6361Q52630015-F1FEB979-AC87-4F8F-910D-08070AAA0C58Q52641743-7638F055-02E9-4BB9-BE5E-1301B9679F63
P2860
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Neurogranin as a Cerebrospinal ...... Symptomatic Alzheimer Disease.
@ast
Neurogranin as a Cerebrospinal ...... Symptomatic Alzheimer Disease.
@en
type
label
Neurogranin as a Cerebrospinal ...... Symptomatic Alzheimer Disease.
@ast
Neurogranin as a Cerebrospinal ...... Symptomatic Alzheimer Disease.
@en
prefLabel
Neurogranin as a Cerebrospinal ...... Symptomatic Alzheimer Disease.
@ast
Neurogranin as a Cerebrospinal ...... Symptomatic Alzheimer Disease.
@en
P2093
P2860
P50
P921
P1433
P1476
Neurogranin as a Cerebrospinal ...... Symptomatic Alzheimer Disease.
@en
P2093
Daniel L Crimmins
Elizabeth M Herries
Jack H Ladenson
Maartje I Kester
P2860
P304
P356
10.1001/JAMANEUROL.2015.1867
P407
P50
P577
2015-09-14T00:00:00Z